Hematological Cancer Report in Advance of ASH

BOSTON—November 24, 2014 -- As the annual American Society of Hematology meeting in San Francisco approaches, the premier source for breaking news and forward-looking analysis of drug developments and forecasting data, BioPharm Insight, today released an Indication Report on the latest developments in leukemia, lymphoma and myeloma including expectations for Novartis’ (VTX:NOVN), Kite Pharma’s (NASDAQ: KITE) and Juno Therapeutics’ treatments for Acute Lymphoblastic Leukemia (ALL).

“We anticipate this year’s ASH conference will be particularly significant for developments in these indication areas,” said BioPharm Insight’s Editor-in-Chief Querida Anderson. “The leukemia, lymphoma and myeloma Indication Report gives readers exclusive insight on major players in this field as well as events we anticipate could move the market.”

Among the conference presentations there will be data presented on chimeric antigen receptor T-cell (CAR-T) therapies by Novartis, Kite Pharma and Juno Therapeutics in acute lymphoblastic leukemia (ALL). Treatments from these three are showing similar complete response rates, although due to the small patient populations, rates may appear different. The report asserts that more time is needed to determine the efficacy and durability of each drug maker’s therapy; all three are in Phase 1 trials.

The BioPharm Insight report also covers expected approval for drugs to treat Chronic Lymphocytic Leukemia (CLL): AbbVie (NYSE:ABBV) and Roche (VTX: ROG), which are together conducting a Phase II trial of ABT-199 (venetoclax) in deletion-17p CLL (del-17p CLL), which will be used for accelerated approval.

In the lymphoma space, closely watched Seattle Genetics’ (NASDAQ: SGEN) Adcetris (brentuximab vedotin) will undoubtedly be part of many conversations at the conference. A Phase II trial of the drug must show at least a 30 percent overall response rate in diffuse large B-cell lymphoma for clinical meaningfulness, and the trial is likely to meet its primary endpoint, though the role of the drug’s target, CD30, is debatable.

Among multiple myeloma drugs, Novartis’ panobinostat will likely need to undergo a new trial to warrant FDA approval. This anticipated outcome follows an unfavorable November 6 vote against the drug by the FDA’s Oncologic Drug Advisory Committee.

Coverage of these developments and others are included in BioPharm Insight’s November 2014 Hematological Cancer Report, available now to all BioPharm Insight subscribers. Non-subscribers may download the report here.

About Infinata’s BioPharm Insight

BioPharm Insight is Infinata’s flagship intelligence solution for the global healthcare markets. With its dedicated team of more than a dozen investigative journalists, BioPharm Insight delivers forward-looking, proprietary intelligence to its subscribers every day. BioPharm Insight’s editorial team covers life sciences from offices in New York and London. Featuring a comprehensive BioPharm Solutions Suite, Infinata provides personalized technology solutions to turn information into insight. Infinata is a part of the Mergermarket Group. To learn more, click here.